Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
How did GNFT's recent EPS compare to expectations?
The most recent EPS for Genfit SA is $, expectations of $.
How did Genfit SA GNFT's revenue perform in the last quarter?
Genfit SA revenue for the last quarter is $
What is the revenue estimate for Genfit SA?
According to 3 of Wall street analyst, the revenue estimate of Genfit SA range from $35.07M to $32.73M
What's the earning quality score for Genfit SA?
Genfit SA has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Genfit SA report earnings?
Genfit SA next earnings report is expected in 2026-02-18
What are Genfit SA's expected earnings?
Genfit SA expected earnings is $, according to wall-street analysts.